MedTrace Logo

A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma

NCT02110355 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2021-03-26

No results posted yet for this study

Summary

Phase 1b/2a, open-label, sequential dose escalation and expansion study of AMG 232 in combination with trametinib and dabrafenib in subjects with metastatic melanoma followed by a direct comparison of AMG 232 combined with trametinib and dabrafenib versus trametinib combined with dabrafenib alone.

Conditions

Interventions

DRUG

AMG 232

Given as an oral tablet in escalating doses

DRUG

Trametinib

Trametinib is an anti-cancer agent

DRUG

Dabrafenib

Dabrafenib is an anti-cancer agent

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • Kartos Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • John Mei · Kartos Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-19
Primary Completion
2018-12-27
Completion
2018-12-27

Countries

  • United States
  • Australia

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02110355 on ClinicalTrials.gov